

# REMARKS

Pursuant to a telephone conversation with the Examiner on 15 October 2007 in the above noted application entry of the above amendments and the following remarks into the record is respectfully requested. Claim 1 is amended to correct for typographical errors present in the R3 moiety, and to more particularly point out and distinctly claim the invention. Applicants agree with the Examiner's statement that correction of said errors is supported in the specification by the working examples and the definition section.

Claims 1 to 5 and 14 to 41 are in the application. Claims 6 to 13 have been cancelled. Claims 14 to 41 have been added. Claims 1, 4, 5 and 11 have been amended. Support for the amendments, and the newly added claims lies in the specification, the working examples and in the claims as filed. Various minor typographical errors throughout the specification has also been made. Applicants reserve their right to file continuation applications on all deleted or cancelled subject matter.

Should the Examiner have any questions or comments he is invited to confer with the Applicants' undersigned agent. If any additional fees or charges are required by this paper the Commissioner is hereby authorized to charge Deposit account 19-2570 accordingly.

Respectfully submitted,



Dara L. Dinner  
Attorney for Applicants  
Registration No. 33,680

GlaxoSmithKline  
Corporate Intellectual Property UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
(610) 270-5017 - telephone  
(610) 270-5090 - facsimile